← Leaderboards
Woodruff Emlen
Taligen Therapeutics, Inc.
$1,018,424
Attributed
$1,018,424
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $555.7K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$1,018,424 · 4
By mechanism
R43$1,018,424 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationLaboratory MouseMonoclonal AntibodyDrug Design /Synthesis /ProductionDisease /Disorder ModelAntigen Antibody ReactionTissue /Cell CultureChronic Disease /DisorderImmunologic Substance Development /PreparationPathologic ProcessTherapy Design /Development
Grant awards (5)
Monoclonal antibody to Factor B as a Therapeutic in Asthma$287,641
R43 · FY2006 · AI · contact PI
The Use of Complement Inhibitors as therapeutic agents in AMD$175,065
R43 · FY2006 · EY · contact PI
Monoclonal Antibody to Factor B as Therapeutic in Asthma$279,700
R43 · FY2005 · AI
Targeted Complement Inhibitors as Therapeutic Agents$178,740
R43 · FY2005 · DK
A Novel Complement Inhibitor for Rheumatoid Arthritis$97,278
R43 · FY2005 · AR